Back to School: How biopharma can reboot drug development. Access exclusive analysis here

PEG-Intron peginterferon alfa-2b: Phase III data; under FDA and EMEA review

ENZN partner Schering-Plough Corp. (SGP, Madison, N.J.) reported results of a 1,219-patient Phase III trial showing

Read the full 160 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE